|
|
Article: Alnylam to Participate in Major Cardiovascular Disease Research Grant Awarded to Scientists at University of Pennsylvania.
- Article from:
- Heart Disease Weekly
- Article date:
- November 15, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced its participation in a $2.4 million research grant awarded to the University of Pennsylvania under the "American Recovery and Reinvestment Act of 2009". The new grant will fund research over two years in the laboratories of Daniel Rader, M.D. of the University of Pennsylvania School of Medicine, Sekar Kathiresan, M.D. of Massachusetts General Hospital (MGH) and Harvard Medical School, and Alnylam (see also Alnylam Pharmaceuticals, Inc.).
The goal of this initiative is to mechanistically evaluate the metabolic and molecular effects of 38 novel genes implicated by human ...